Industry Facts

SFA Therapeutics, a clinical-stage biopharmaceutical company, has announced that it has appointed Dr Anada Gubbi as director of Biostatistics. Dr Gubbi will be responsible for assisting SFA Therapeutics in effectively developing drug candidates for the treatment of inflammatory diseases.

Dr Gubbi received his PhD in Mathematical Sciences from the University of Memphis, US. Most recently, Dr Gubbi served as a consultant for biostatistics in the pharmaceutical industry as well as at Slippery Rock University, PA, US.

“SFA Therapeutics’ novel platform has the potential to make significant contributions to the immunology and anti-inflammatory disease space with the ability to tailor biosynthetic compounds with target-specific adjuvants. I look forward to applying my biostatistical and computing skill set to obtain insights from clinical trials and results for SFA-002 and other therapeutic candidates,” commented Dr Gubbi.

Previously, Dr Gubbi was the associate director of Biostatistics at CPC Clinical Services, where he managed the analysis of 18 clinical studies. He has also held positions as a biostatistician at Amgen, Teva Pharmaceuticals, Kite Pharmaceuticals, Genentech, Sanofi-Aventis Pharmaceuticals, Schering-Plough, Pharmacia-Upjohn and Boehringer Ingelheim. He trained initially at the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) as a statistical reviewer, where he developed his skillset in clinical trials.